Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Processa Pharmaceuticals ( (PCSA) ) has shared an update.
On January 6, 2026, Processa Pharmaceuticals, Inc. announced that it had regained compliance with the Nasdaq Capital Market’s $1.00 minimum closing bid price requirement for continued listing, and Nasdaq has formally closed the matter. This resolution removes an immediate delisting risk for the company’s shares and stabilizes its stock market status, which may provide greater confidence and certainty for investors and other stakeholders.
The most recent analyst rating on (PCSA) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Processa Pharmaceuticals stock, see the PCSA Stock Forecast page.
Spark’s Take on PCSA Stock
According to Spark, TipRanks’ AI Analyst, PCSA is a Neutral.
The score is driven primarily by weak financial performance (pre-revenue status, ongoing losses, and negative/free cash flow with rising burn), followed by bearish technicals (price below major moving averages and negative MACD). Valuation contributes minimally because negative earnings make P/E less informative and there is no dividend yield.
To see Spark’s full report on PCSA stock, click here.
More about Processa Pharmaceuticals
Average Trading Volume: 944,521
Technical Sentiment Signal: Strong Sell
Current Market Cap: $7.32M
For a thorough assessment of PCSA stock, go to TipRanks’ Stock Analysis page.